Moderna Inc.
Moderna Reports Q2 2026 Financial Results and Pipeline Updates
Summary
Moderna, Inc. reported second quarter 2026 financial results with total revenue of $145 million, GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The company reiterated its plan for up to 10% revenue growth in 2026 and improved its 2026 operating expense outlook by approximately $0.2 billion. Moderna anticipates potential approval of its seasonal influenza vaccine candidate, mFLUSIVA, with an August 5th PDUFA date. The company also announced that its norovirus vaccine candidate, mRNA-1403, did not meet statistical criteria for early success at the Phase 3 interim analysis and is preparing to enroll an additional cohort. Corporate updates include the appointment of Ester Banque as Chief Commercial Officer and Michael McDonnell to the Board of Directors.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement